



IMAGING OF PARKINSON'S DISEASE AND PARKINSONISMS

Alessandro Tessitore

Movement Disorders Unit – Dept. of Neurology
MRI Research Center
University of Campania – “Luigi Vanvitelli”
alessandro.tessitore@unicampania.it



V: Università
degli Studi
della Campania
Luigi Vanvitelli

www.napoliparkinson.it



Disclosures

- Received speaker honoraria and/or research funding from Abbvie, Bial, UCB pharma, Sanofi, Zambon
- Received funding for travel from Abbvie, Bial, UCB pharma, Zambon, Lundbeck, Lusofarmaco
- Serves as a member of the Editorial Board of Parkinsonism and Related Disorders journal

Learning objective(s)

Upon completion of this talk, participants will be able to:

- Utilize imaging methods for differential diagnosis and evaluation of distinct movement disorders syndromes
- Identify neuroimaging biomarkers of prodromal and early Parkinson's disease
- Recognize imaging markers for differential diagnosis of movement disorders in clinical practice



Key messages

- Modern MRI approaches have unveiled several complementary markers that are useful for research and clinical application.
- These markers are useful for the diagnosis of PD and atypical parkinsonisms, to track disease progression from the premotor stages and to better understand the neurobiological basis of clinical deficits.
- Iron- and neuromelanin-sensitive MRI detect qualitative changes in the substantia nigra and can be useful to support a clinical diagnosis of Parkinson's disease but cannot differentiate between parkinsonian disorders.



References

- Lehericy S, Vaillancourt DE, Seppi K, et al. (IPMDS)-Neuroimaging Study Group. The role of high-field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward. *Mov Disord*. 2017 Apr;32(4):510-525. doi: 10.1002/mds.26968.
- Strafella AP, Bohnen NI, Pavese N et al. IPMDS-Neuroimaging Study Group. Imaging Markers of Progression in Parkinson's Disease. *Mov Disord Clin Pract*. 2018 Oct 9;5(6):586-596. doi: 10.1002/mdc3.12673
- van Eimeren T, Antonini A, Berg D et al. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. *Alzheimers Dement (Amst)*. 2019 Apr 2;11:301-309. doi: 10.1016/j.dadm.2019.01.011